spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  PD-L1 

 HSMN NewsFeed - 6 Jun 2024
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Apr 2023
Strata Oncology Announces Launch and Medicare Coverage for Strata Select, a First-of-its-kind Immunotherapy Test
Diagnostics Oncology Product Launch Reimbursement
 HSMN NewsFeed - 31 May 2022
Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2022
Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
Diagnostics
 HSMN NewsFeed - 19 Jul 2021
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2021
Sirnaomics Secures $105 Million in Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jun 2021
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Mar 2021
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Aug 2020
Phosplatin Therapeutics Completes $18.4 Million Private Financing Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2020
KAHR Medical Raises $18 Million in Private Funding Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2019
IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win(R) Immunotherapy in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Mar 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Urology Oncology
 HSMN NewsFeed - 10 Dec 2018
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Dec 2018
CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Nov 2018
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2018
Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Aug 2018
IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Jul 2018
SeraCare Announces the Expansion of Their Proprietary AccuPlex(TM) Technology Product Portfolio with the Launch of the AccuSpan(TM) HCV RNA Linearity Panel
Diagnostics Product Launch
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2018
Caris Life Sciences Expands Management Team
Diagnostics Personnel
 HSMN NewsFeed - 21 Jun 2018
Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
Diagnostics Oncology
 HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jun 2018
IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jun 2018
Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Mar 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2018
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Dec 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 14 Nov 2017
NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Sep 2017
Esteemed Researcher and Clinical Oncologist W. Michael Korn, M.D. Joins Caris Life Sciences as Chief Medical Officer
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2017
Caris Life Sciences Appoints John Marshall, M.D., as Chief Medical Officer
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Mar 2017
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch
 HSMN NewsFeed - 20 Mar 2017
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody(TM) Therapeutics for the Treatment of Cancer and Other Diseases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2017
Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Oct 2016
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Oct 2016
Agilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer (NSCLC)
Diagnostics Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Aug 2016
Tioma Therapeutics Announces $86 Million Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Aug 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2016
Personal Genome Diagnostics Names Abigail McElhinny Senior Vice President of Research & Development, Operations
Diagnostics Oncology Personnel
 HSMN NewsFeed - 26 Apr 2016
Hematogenix Laboratory Services, LLC (Hematogenix)- Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immuno-Oncology Therapies
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA
 HSMN NewsFeed - 30 Mar 2016
Curis Announces Expansion of Executive Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jan 2016
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2015
Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2015
Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Oct 2015
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Sep 2015
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2015
CytomX Announces Management Team Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jul 2015
Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jul 2015
In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 8 May 2015
Provectus Biopharmaceuticals Updates Market on Business Developments
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 28 Apr 2014
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Jan 2014
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jan 2014
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Dec 2013
Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2013
OncoSec Medical Announces Hire of Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Aug 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
PD-L1
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.